About the Company
Established in 2011, OncoSec Medical Incorporated is a San Diego-based biotechnology company pioneering new technologies to stimulate the body’s immune system to target and attack cancer. Through our proprietary technology, we hope to deliver safer and more effective cancer treatments that can provide long-term benefits for patients.
OncoSec’s investigational platform, ImmunoPulse®, is designed to enhance local delivery and uptake of DNA-based therapeutics directly into tumors. Clinical studies of ImmunoPulse® with DNA-based IL-12 demonstrated a local immune response, and subsequently, a systemic effect. We are currently conducting pre-clinical and clinical studies targeting various cancers in collaboration with several prominent academic medical centers and companies.
To date, study results have laid the groundwork for OncoSec’s expansion into new DNA-encoded therapeutic candidates and tumor indications. Data also indicates this platform shows clinical activity as a monotherapy and promise as a combination approach.
OncoSec Announces Dosing of First Patient in Registration-Directed Phase 2b Clinical Trial, PISCES/KEYNOTE-695, of ImmunoPulse® IL-12 in Combination with Pembrolizumab
SAN DIEGO, Dec. 14, 2017 /PRNewswire/ — OncoSec Medical Incorporated (“OncoSec” or the “Company”) (ONCS), a company developing intratumoral cancer immunotherapies, today announced the initiation of patient dosing in PISCES/KEYNOTE-695, the company’s global, multi-center, registration-directed open-label Phase 2b clinical trial. The trial will...
SAN DIEGO, Dec. 5, 2017 /PRNewswire/ — OncoSec Medical Incorporated (“OncoSec”) (ONCS), a company developing intratumoral cancer immunotherapies, today announced the promotion of Christopher G. Twitty, Ph.D. to Chief Scientific Officer. Dr. Twitty joined OncoSec in 2016 as Executive Director of Clinical Science....
OncoSec Expands Intellectual Property Estate, Announces Issuance of Patents for ImmunoPulse® Platform
SAN DIEGO, Nov. 28, 2017 /PRNewswire/ — OncoSec Medical Incorporated (“OncoSec” or the “Company”) (NASDAQ:ONCS), a company developing intratumoral cancer immunotherapies, today announced that it has added two patents to its broad patent portfolio. The first patent, JP06174632, encompasses a device...
OncoSec Announces Preclinical Data Demonstrating Multi-Gene Expression Platform for Delivery of Multiple Cancer Immunotherapies at the Society for Immunotherapy of Cancer (SITC) Annual Meeting 2017
OncoSec’s Polycistronic Interleukin-12 Immune Modulator (PIIM) DNA Plasmid Vector Enables Simultaneous Delivery of Multiple Complementary Anti-Cancer Agents OncoSec Presents Emerging Preclinical Data Demonstrating its Novel Platform at the Society for Immunotherapy of Cancer (SITC) 32nd Annual Meeting SAN DIEGO, Nov....